To evaluate the risk of long-term tumor recurrence and progression in patients with low- and intermediate-risk non-muscle-invasive bladder cancers, which could facilitate optimization in the follow-up schedules.
Materials and Methods
A single-institution, retrospective analysis of 704 patients with primary TaG1, TaG2, T1G1, and T1G2 urothelial carcinomas of the bladder without concomitant carcinoma in situ, treated with transurethral resection, was performed. Response was determined and monitored by routine periodic urine cytology, cystoscopy, and upper tract imaging.
The median follow-up was 64.9 months (maximum, 120 months). Among all of the tumors, 59.3% did not relapse, 36.6% recurred in the bladder during the first 5 years of surveillance, and only 3.6% recurred after 5 years of follow-up. Eight urothelial bladder cancers (1.1%) progressed in stage, and 87.5% of the progressions occurred during the first 5 years of surveillance. An upper urinary tract recurrence was detected in 2.4% of the patients; 94.1% were diagnosed within the upper urinary tract during the first 5 years of follow-up and 5.9% occurred after 5 years of surveillance.
G1-2 urothelial bladder cancers recur and progress uncommonly in the long-term period. Although limited by its retrospective nature, the present study provides potential grounds for re-examination of the follow-up schedule for patients with primary non-muscle-invasive bladder cancer G1-2 tumors who remain asymptomatic and disease-free for at least 5 years.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Urology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.Eur Urol. 2013; 64: 639-653
- Conservative management of low risk superficial bladder tumors.J Urol. 2008; 179 (discussion 90): 87-90
- Disease specific mortality in patients with low risk bladder cancer and the impact of cystoscopic surveillance.J Urol. 2013; 189: 828-833
- Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.Eur Urol. 2006; 49: 466-475
- Low risk bladder tumors–less is more!.J Urol. 2008; 179: 13-14
- Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder.J Urol. 1999; 162: 1946-1950
- Pattern of recurrence changes in noninvasive bladder tumors observed during 2 decades.J Urol. 2007; 177: 867-875
- Late recurrence and progression in non-muscle-invasive bladder cancers after 5-year tumor-free periods.Urology. 2010; 75: 1385-1390
- The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years.J Urol. 1995; 153: 1823-1826
- Urological tumours: bladder. TNM classification of malignant tumors.in: Sobin L.H. Gospodarowicz M. Wittekind C. UICC International Union Against Cancer. 7th ed. Wiley-Blackwell, Hoboken, NJ2009: 262-265
- Histological Typing of Urinary Bladder Tumors. International Classification of Tumors No 10.WHO, Geneva1973
- Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer.Eur Urol. 2013; 63: 145-154
- Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder.Eur Urol. 2014; 65: 201-209
- Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.J Urol. 2009; 182: 2195-2203
- Long-term follow-up of noninvasive bladder tumours (stage Ta): recurrence and progression.BJU Int. 2000; 85: 824-828
- Predictors of upper tract urothelial cell carcinoma after primary bladder cancer: a population based analysis.J Urol. 2009; 181: 1035-1039
- Upper urinary tract tumors developing after treatment of superficial bladder cancer: 7-year follow-up of 591 consecutive patients.Urology. 1999; 53: 1144-1148
- A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials.J Urol. 2004; 171: 2186-2190
- Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis.J Natl Compr Canc Netw. 2013; 11: 477-484
- Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review.Eur Urol. 2013; 64: 421-430
- Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results.Eur Urol. 2008; 53: 45-52
- A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences.J Urol. 2008; 179: 101-105
- Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.Eur Urol. 2009; 55: 773-780
- EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder.Eur Urol. 2008; 54: 303-314
- The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.J Urol. 2006; 175: 1641-1644
- A second-look TUR in T1 transitional cell carcinoma: why?.Eur Urol. 2004; 45: 539-546
Published online: October 17, 2016
Accepted: July 23, 2016
Received: March 23, 2016
Financial Disclosure: The authors declare that they have no relevant financial interests.
© 2016 Elsevier Inc. All rights reserved.